RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

JOURNAL ARTICLE published 10 November 2011 in Journal of Clinical Oncology

Authors: Adam M. Brufsky | Sara Hurvitz | Edith Perez | Raji Swamy | Vicente Valero | Vincent O'Neill | Hope S. Rugo